The entire commercial logic this series has examined from the MR-driven detailing model in Episode 8, the chronic refill economics implicit in the GLP-1 story in Episode 5 , assumes a patient who keeps coming back. Cell and gene therapy breaks that assumption completely. CGT is often a single infusion, priced once, intended to either cure the patient or durably control the disease, eliminating the recurring revenue stream entirely.

NexCAR19’s journey from a ₹42 lakh launch price to a ₹30 lakh price, alongside its first full year of real profitability, shows India is not just a low-cost copier of this model but an active participant proving a harder economic problem can be solved, making a curative, one-time therapy commercially sustainable at a fraction of Western pricing.

• The actual chronic-care cost stack for relapsed/refractory blood cancers in India — BMT, multi-line chemotherapy, targeted therapy — set directly against NexCAR19’s single ₹30 lakh dose

• ImmunoACT’s real financial trajectory: ₹42 lakh to ₹30 lakh pricing, ₹62 crore revenue and ₹12 crore profit in FY25, 350+ patients treated across 70 hospitals

• Why a one-time cure is a harder business model to sustain profitably than a chronic therapy, and what ImmunoACT’s manufacturing scale-up reveals about solving that problem

• What this means for Indian pharma companies whose commercial and financial architecture, examined in Episodes 7 and 8, is built entirely around recurring revenue

Listen in to Episode 8 of the Bio-Health Supercycle.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Episode ID: 1000774815824

GUID: substack:post:204229563

Release Date: 30/06/2026, 13:29:41